Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Efficacy, Safety, and Tolerability of Adjunctive Eslicarbazepine Acetate in Focal Seizure Patients With Focal to Bilateral Tonic-Clonic Seizures at Baseline
Epilepsy/Clinical Neurophysiology (EEG)
P14 - Poster Session 14 (11:45 AM-12:45 PM)
9-003
ESL is approved for focal seizure treatment. FBTCS are the most severe form of focal seizures and place patients at increased risk of injuries and sudden unexpected death. 
Here we report the efficacy, safety, and tolerability of eslicarbazepine acetate (ESL) in patients who experienced baseline focal to bilateral tonic-clonic seizures (FBTCS).

Pooled data from 3 randomized clinical trials of ESL in patients with focal seizures (N=1447) were analyzed. After an 8-week baseline, patients were titrated over 2 weeks to their maintenance dose (400, 800, or 1200 mg/day; 12 weeks). Efficacy was assessed in a patient subset with ≥1 baseline FBTCS and ≥800 mg/day ESL maintenance dose by comparing standardized seizure frequency (SSF, FBTCS/28 day) during the maintenance period with placebo. Adverse events (AEs) were collected and tabulated.

A total 438 patients, aged 16-69, met the subset criteria and 429 patients had ≥1 post-baseline seizure diary entry. Baseline characteristics were balanced among treatment groups. Baseline median FBTCS SSF was 2.5 (placebo), 2.5 (ESL 800mg), and 2.4 (ESL 1200mg). During maintenance, the FBTCS SSF was lower in ESL groups (800mg, 0.9; 1200mg, 0.8) compared to placebo (1.1), and was significant for ESL 1200mg (P=0.0395, ANCOVA). ESL 1200mg patients achieved ≥50% reduction in SSF (61.9%, P=0.005, Cochran-Mantel-Haenszel test) or ≥75% reduction in SSF (46.0%, P=0.0315) at greater rates versus placebo (≥50%, 45.6%; ≥75%, 33.3%). Time to first seizure was significantly longer in ESL groups than placebo (Kaplan-Meier). Incidence of AEs and AEs leading to discontinuation increased with ESL dose. 

Adjunctive ESL was well-tolerated and increased time to first seizure for patients with FBTCS. ESL 1200mg significantly improved 50% and 75% responder rates compared to placebo. ESL may be a useful treatment option for FBTCS.

Authors/Disclosures
Steve S. Chung, MD, FAAN (Banner University Medical Center)
PRESENTER
The institution of Dr. Chung has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ucb pharma. Dr. Chung has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SK Life sciences. Dr. Chung has received personal compensation in the range of $500-$4,999 for serving as a Consultant for eisai. Dr. Chung has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for eisai. Dr. Chung has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for ucb. Dr. Chung has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK Life sciences. Dr. Chung has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for sunovion.
Samy M. Guirguis, MD (SK Life Science) No disclosure on file
David Cantu, PhD (Sunovion Pharmaceuticals Inc. ) Dr. Cantu has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
Joana Moreira Joana Moreira has received personal compensation for serving as an employee of BIAL.
Luis Magalhaes (Bial-Portela & C S.A.) Luis Magalhaes has received personal compensation for serving as an employee of BIAL-Portela & Cª, S.A..
Diane Hall (Sunovion Pharmaceuticals Inc.) Ms. Hall has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
Ian Zhang Ian Zhang has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
Todd Grinnell, PhD Todd Grinnell, PhD has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..